Clinical Outcomes and Persistence of Somatic Mutations in Acute Myeloid Leukemia Patients after Transplantation

Allogeneic hematopoietic stem cells transplant (HSCT) is a curative treatment for acute myeloid leukemia (AML). The persistence of disease-associated somatic mutations following HSCT for myelodysplastic syndrome has been shown to be associated with a high risk of disease progression. While a recent study in AML found that the presence of somatic mutations at day 21 post-HSCT is associated with higher risk of relapse, there is paucity of data at a later time point. We hypothesized that persistence of mutations at day 100 resulted in increased relapse rates and inferior outcomes than in patients who had cleared their mutations.

Source: Biology of Blood and Marrow Transplantation - January 31, 2019 Category: Hematology Authors: Ayman Qasrawi, Zin Myint, Rani Jayswal, Ranjana Arora, Hayder Saeed, Gregory Monohan, Roger Herzig, Gerhard C Hildebrandt, Reshma Ramlal Tags: 138 Source Type: research